Suppr超能文献

对乙酰氨基酚最大日剂量对酒精性肝病患者肝脏的影响:一项随机、双盲、安慰剂对照试验。

Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial.

作者信息

Kuffner E K, Dart R C, Bogdan G M, Hill R E, Casper E, Darton L

机构信息

Rocky Mountain Poison and Drug Center, 1010 Yosemite Cir, Denver, CO 80230, USA.

出版信息

Arch Intern Med. 2001 Oct 8;161(18):2247-52. doi: 10.1001/archinte.161.18.2247.

Abstract

BACKGROUND

Retrospective reports suggest that therapeutic doses of acetaminophen may be associated with fulminant hepatic failure and death in alcoholic patients. Millions of patients use acetaminophen; the prevalence of alcoholism in the United States is 5% to 10%.

OBJECTIVE

To determine if hepatic injury was associated with maximal therapeutic dosing of acetaminophen to chronic alcohol abuse patients immediately following cessation of alcohol intake (the presumed time of maximal vulnerability).

METHODS

Patients entering an alcohol detoxification center were enrolled in a randomized, double-blind, placebo-controlled trial. Exclusion criteria were baseline values of aspartate or alanine aminotransferase greater than 120 U/L, international normalized ratio greater than 1.5, serum acetaminophen level greater than 20 mg/L, or a history of ingesting more than 4 g/d of acetaminophen. Acetaminophen, 1000 mg, or placebo was administered orally 4 times daily for 2 consecutive days and liver test results were monitored for 2 more days. Acetaminophen was not administered until the alcohol had been eliminated.

RESULTS

There were 102 patients in the acetaminophen-treated group and 99 patients in the placebo-treated (control) group. Demographic data, alcohol history, and baseline blood test results were similar in both groups. The mean (SD) aspartate aminotransferase level on day 4 was 38.0 +/- 26.7 U/L in the acetaminophen-treated group and 37.5 +/- 27.6 U/L in the placebo-treated group. There were 4 patients in the acetaminophen-treated group and 5 in the placebo-treated group who developed an increase in their serum aspartate aminotransferase level to greater than 120 U/L; it did not exceed 200 U/L in any patient. The mean (SD) international normalized ratio on day 4 was 0.96 +/- 0.09 in the acetaminophen-treated group and 0.98 +/- 0.11 in the placebo-treated group.

CONCLUSION

Repeated administration of the maximum recommended daily doses of acetaminophen to long-term alcoholic patients was not associated with evidence of liver injury.

摘要

背景

回顾性报告表明,对酒精性患者使用治疗剂量的对乙酰氨基酚可能与暴发性肝衰竭及死亡有关。数以百万计的患者使用对乙酰氨基酚;美国酗酒的患病率为5%至10%。

目的

确定在慢性酒精滥用患者停止饮酒后(假定为最大易损期)立即给予对乙酰氨基酚最大治疗剂量是否与肝损伤有关。

方法

进入酒精解毒中心的患者参加一项随机、双盲、安慰剂对照试验。排除标准为天冬氨酸或丙氨酸转氨酶基线值大于120 U/L、国际标准化比值大于1.5、血清对乙酰氨基酚水平大于20 mg/L或有摄入超过4 g/d对乙酰氨基酚的病史。对乙酰氨基酚1000 mg或安慰剂连续2天每天口服4次,并再监测2天肝功能检查结果。在酒精清除之前不给予对乙酰氨基酚。

结果

对乙酰氨基酚治疗组有102例患者,安慰剂治疗(对照)组有99例患者。两组的人口统计学数据、饮酒史和基线血液检查结果相似。对乙酰氨基酚治疗组第4天天冬氨酸转氨酶平均(标准差)水平为38.0±26.7 U/L,安慰剂治疗组为37.5±27.6 U/L。对乙酰氨基酚治疗组有4例患者、安慰剂治疗组有5例患者血清天冬氨酸转氨酶水平升高至大于120 U/L;所有患者均未超过200 U/L。对乙酰氨基酚治疗组第4天国际标准化比值平均(标准差)为0.96±0.09,安慰剂治疗组为0.98±0.11。

结论

对长期酗酒患者重复给予对乙酰氨基酚最大推荐日剂量与肝损伤证据无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验